298 related articles for article (PubMed ID: 8612581)
1. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
Resnati M; Guttinger M; Valcamonica S; Sidenius N; Blasi F; Fazioli F
EMBO J; 1996 Apr; 15(7):1572-82. PubMed ID: 8612581
[TBL] [Abstract][Full Text] [Related]
2. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
3. Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence.
Chiaradonna F; Fontana L; Iavarone C; Carriero MV; Scholz G; Barone MV; Stoppelli MP
EMBO J; 1999 Jun; 18(11):3013-23. PubMed ID: 10357814
[TBL] [Abstract][Full Text] [Related]
4. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
5. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.
Fazioli F; Resnati M; Sidenius N; Higashimoto Y; Appella E; Blasi F
EMBO J; 1997 Dec; 16(24):7279-86. PubMed ID: 9405357
[TBL] [Abstract][Full Text] [Related]
6. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
7. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck).
Trigwell S; Wood L; Jones P
Biochem Biophys Res Commun; 2000 Nov; 278(2):440-6. PubMed ID: 11097855
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
Yebra M; Goretzki L; Pfeifer M; Mueller BM
Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
[TBL] [Abstract][Full Text] [Related]
10. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
11. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
12. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
13. Structure and function of the urokinase receptor.
Mondino A; Resnati M; Blasi F
Thromb Haemost; 1999 Sep; 82 Suppl 1():19-22. PubMed ID: 10695480
[TBL] [Abstract][Full Text] [Related]
14. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
[TBL] [Abstract][Full Text] [Related]
15. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R.
Resnati M; Pallavicini I; Wang JM; Oppenheim J; Serhan CN; Romano M; Blasi F
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1359-64. PubMed ID: 11818541
[TBL] [Abstract][Full Text] [Related]
16. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
17. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
18. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
19. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Guthaus E; Bürgle M; Schmiedeberg N; Hocke S; Eickler A; Kramer MD; Sweep CG; Magdolen V; Kessler H; Schmitt M
Biol Chem; 2002 Jan; 383(1):207-16. PubMed ID: 11930939
[TBL] [Abstract][Full Text] [Related]
20. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
